FIELD: molecular biology, medicine, immunology. SUBSTANCE: invention relates to preparing monoclonal antibodies showing immunostimulating effect. Hybridoma CNCM 1-1397 is prepared by immunization of mice with membrane preparation of Daudi cells followed by isolation of splenocytes and their fusion with myeloma cells. Hybridoma produces monoclonal antibodies showing immunostimulating effect and able to bind CD3 cells. Invention ensures to develop antitumor preparation that can be used for treatment and prophylaxis of cancer. EFFECT: valuable antitumor properties. 4 cl, 12 dwg, 12 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY, NUCLEIC ACID AND VECTOR ENCODING ANTIBODY AND USING ANTIBODY FOR DIAGNOSIS AND TREATMENT OF MALIGNANT DISEASE | 1999 |
|
RU2235131C2 |
| SOLUBLE CEA-STABLE PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2573893C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| VERSIONS OF HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES | 2012 |
|
RU2604814C2 |
| METHODS AND COMPOSITION USEFUL FOR ANGIOGENESIS INHIBITION | 1995 |
|
RU2162712C2 |
| METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
| CONJUGATE OF ANTIMELANOMA ANTIBODY AND CYTOTOXIC AGENT AND A METHOD OF MELANOMA INHIBITION | 1991 |
|
RU2119352C1 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
| USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
